Biomarkers: FDA Working To Define 'Reasonably Likely To Predict' Standard
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration wants to help expand biomarker use as surrogate endpoints, but is encouraging pharma companies and researchers to create common evidentiary standards and vocabulary for their development.